Trypsinogen‐loaded nanoparticles reprogram TAMs via NF‐κB/NLRP3, driving M2→M1 conversion and potent phagocytosis to unleash antitumor immunity. ABSTRACT Although reprogramming tumor‐associated macrophages (TAMs) represents a promising therapeutic strategy, approaches that are both precise and safe remain scarce.
Lei Cao +7 more
wiley +1 more source
Impact of SARS-CoV-2 Breakthrough Infection on Short-Term CD4 Count Among Adults With HIV in the United States From 2020 to 2022. [PDF]
Hopkins L +13 more
europepmc +1 more source
Penfluridol Triggers GSDME‐Mediated Immunogenic Pyroptosis to Potentiate Antitumor Immunotherapy
A high‐throughput screen of FDA‐approved antipsychotics identifies penfluridol as a potent pyroptosis inducer acting via direct TTI1 inhibition. This triggers TNFA‐NFKB signaling and caspase‐8/‐3‐dependent GSDME cleavage. The compound stimulates antitumor immunity alone and synergizes with anti‐PD‐1 therapy, while low TTI1 expression emerges as a ...
Linfeng Li +11 more
wiley +1 more source
Type-1 inflammatory imprinting and programmed responsiveness to CD40L enhance Siglec-1-dependent HIV-1 trans-infection by dendritic cells. [PDF]
Bothwell EG +11 more
europepmc +1 more source
CD73 activity controls cytotoxic CD4 T-cell response driving myocardial pathology in chronic Chagas disease. [PDF]
Bergero G +5 more
europepmc +1 more source
Long-acting IL-7 restores T-cell reconstitution in a humanized mouse model of lymphopenia. [PDF]
Pérez-Díez A +8 more
europepmc +1 more source
Machine learning risk stratification to identify people living with HIV at high risk of delayed ART and advanced immunosuppression: a precision public health approach. [PDF]
Yin J +8 more
europepmc +1 more source
Single-cell T-cell landscape in atherosclerosis: implications for targeted therapy and beyond. [PDF]
Luo R, Liu S, Ouyang X, Zhou E, Jiang L.
europepmc +1 more source
Profound immune suppression and exhaustion characterize refractory mycoplasma pneumoniae pneumonia in children. [PDF]
Ma X, Wu Y, He F, Yao H, Cao L, Zhu C.
europepmc +1 more source

